Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.56 |
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | SORD | Q00796 | 3/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325685 | 0.89 | AR (0.57) | MTORARPIK3CAPIK3CDKMT2A | |
| SCHEMBL8251599 | 0.80 | AR (0.58) | MTORARPIK3CAKMT2AALDH1A1 | |
| SCHEMBL5457199 | 0.79 | PIK3CA (0.55) | MTORPIK3CAPIK3CDKMT2AMEN1 | |
| SCHEMBL17014730 | 0.77 | AR (0.55) | MTORARPIK3CAPIK3CDKMT2A | |
| SCHEMBL20000530 | 0.75 | PIK3CA (0.51) | MTORPIK3CAPIK3CDKMT2AMEN1 | |
| SCHEMBL3326479 | 0.75 | MTOR (0.43) | MTORPIK3CAPIK3CDKMT2AMEN1 | |
| SCHEMBL21914804 | 0.75 | PIK3CA (0.50) | PIK3CAPIK3CDKMT2AMEN1USP2 | |
| SCHEMBL29790016 | 0.75 | PIK3CA (0.50) | PIK3CAPIK3CDKMT2AMEN1USP2 | |
| SCHEMBL3326770 | 0.73 | MTOR (1.00) | MTORPIK3CAPIK3CDATRATRIP | |
| SCHEMBL19725018 | 0.73 | PIK3CA (0.49) | MTORPIK3CAPIK3CDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| CN-101128440-A | Hydrazinomethyl, hydrazonomethyl and 5-membered heterocyclic compounds as mTOR inhibitors and their use as anti-cancer agents | KUDOS PHARM LTD (GB) | 2008-02-20 | — | — | CN | disclosed |
| EP-1877388-A2 | HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199804-A1 | Compounds | CA4, CA6, CYP2B6 | MTOR 3648/4885AR 1581/4885PIK3CA 2265/4885 |
| US-20100130473-A1 | COMPOUNDS | CA6, CYP2B6, CA4 | MTOR 3596/4885AR 1477/4885PIK3CA 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.